Humacyte (NASDAQ:HUMA) Rating Lowered to Sell at Wall Street Zen

Humacyte (NASDAQ:HUMA) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Friday.

Several other research analysts have also recently weighed in on HUMA. Benchmark dropped their price objective on shares of Humacyte from $17.00 to $14.00 and set a “buy” rating for the company in a research report on Wednesday, May 14th. HC Wainwright began coverage on shares of Humacyte in a research report on Wednesday, May 14th. They set a “buy” rating and a $4.00 target price for the company. Finally, D. Boral Capital reiterated a “buy” rating and set a $25.00 target price on shares of Humacyte in a research report on Wednesday, July 9th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.71.

Humacyte Stock Performance

HUMA stock opened at $2.33 on Friday. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.68 and a quick ratio of 3.28. The company has a 50 day moving average price of $2.35 and a 200 day moving average price of $2.79. Humacyte has a fifty-two week low of $1.15 and a fifty-two week high of $9.79. The stock has a market capitalization of $361.43 million, a PE ratio of -3.38 and a beta of 1.89.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.09. The company had revenue of $0.52 million during the quarter, compared to the consensus estimate of $0.46 million. Analysts forecast that Humacyte will post -1.27 EPS for the current year.

Hedge Funds Weigh In On Humacyte

Several institutional investors and hedge funds have recently made changes to their positions in the company. Beacon Pointe Advisors LLC grew its holdings in shares of Humacyte by 33.3% in the 4th quarter. Beacon Pointe Advisors LLC now owns 20,000 shares of the company’s stock valued at $101,000 after buying an additional 5,000 shares during the period. Teacher Retirement System of Texas grew its holdings in shares of Humacyte by 25.3% in the 4th quarter. Teacher Retirement System of Texas now owns 26,200 shares of the company’s stock valued at $132,000 after buying an additional 5,293 shares during the period. Wealth Effects LLC grew its holdings in shares of Humacyte by 5.8% in the 2nd quarter. Wealth Effects LLC now owns 102,167 shares of the company’s stock valued at $214,000 after buying an additional 5,600 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of Humacyte by 20.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 33,870 shares of the company’s stock valued at $172,000 after buying an additional 5,801 shares during the period. Finally, MetLife Investment Management LLC grew its holdings in shares of Humacyte by 14.4% in the 1st quarter. MetLife Investment Management LLC now owns 51,442 shares of the company’s stock valued at $88,000 after buying an additional 6,482 shares during the period. Institutional investors and hedge funds own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.